Literature DB >> 20141357

Severe retinopathy of prematurity associated with FZD4 mutations.

Anna Ells1, Duane L Guernsey, Karin Wallace, Binyou Zheng, Michael Vincer, Alexander Allen, April Ingram, Orlando DaSilva, Lee Siebert, Thomas Sheidow, Jill Beis, Johane M Robitaille.   

Abstract

PURPOSE: To determine whether mutations in the FZD4 gene are a risk factor for developing severe ROP.
METHODS: Three Canadian tertiary care centers recruited premature infants prospectively and retrospectively, and assigned affectation status based on the maximum degree of severity of ROP recorded in both eyes. Mutation screening of the FZD4 gene was performed using direct sequencing. All sequence changes were evaluated for functional significance.
RESULTS: Two novel FZD4 mutations (Ala370Gly or Lys203Asn) were identified in two infants from the severe ROP group (n=71). No mutation was detected in the mild to no ROP group (n=33), and the two novel mutations were absent in 173 random Caucasian samples. Mutation Ala370Gly was also found in one sibling and one parent of the affected infant, but no signs of familial exudative vitreoretinopathy (FEVR), a condition with phenotypic overlap with ROP known to be caused by FZD4 mutations, were present in either family member.
CONCLUSIONS: Mutations in the FZD4 gene in this group of premature infants supports a role for the FZD4 pathway in the development of severe ROP and accounts for approximately 3% of severe ROP in Caucasian premature infants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20141357     DOI: 10.3109/13816810903479834

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  22 in total

Review 1.  Wnt Signaling in vascular eye diseases.

Authors:  Zhongxiao Wang; Chi-Hsiu Liu; Shuo Huang; Jing Chen
Journal:  Prog Retin Eye Res       Date:  2018-12-01       Impact factor: 21.198

Review 2.  Genomics in the neonatal nursery: Focus on ROP.

Authors:  Mary Elizabeth Hartnett; C Michael Cotten
Journal:  Semin Perinatol       Date:  2015-10-23       Impact factor: 3.300

Review 3.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 4.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

Review 5.  Current update on retinopathy of prematurity: screening and treatment.

Authors:  Jing Chen; Andreas Stahl; Ann Hellstrom; Lois E Smith
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

Review 6.  Familial exudative vitreoretinopathy and related retinopathies.

Authors:  D F Gilmour
Journal:  Eye (Lond)       Date:  2014-10-17       Impact factor: 3.775

7.  Risk factors for retinopathy of prematurity: insights from outlier infants.

Authors:  Alexander D Port; R V Paul Chan; Susan Ostmo; Dongseok Choi; Michael F Chiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-23       Impact factor: 3.117

8.  Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants.

Authors:  M Elizabeth Hartnett; Margaux A Morrison; Silvia Smith; Tammy L Yanovitch; Terri L Young; Tarah Colaizy; Allison Momany; John Dagle; Waldemar A Carlo; Erin A S Clark; Grier Page; Jeff Murray; Margaret M DeAngelis; C Michael Cotten
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-12       Impact factor: 4.799

Review 9.  Genetic susceptibility to advanced retinopathy of prematurity (ROP).

Authors:  Barkur S Shastry
Journal:  J Biomed Sci       Date:  2010-08-25       Impact factor: 8.410

10.  Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity.

Authors:  Hiroyuki Kondo; Shunji Kusaka; Aki Yoshinaga; Eiichi Uchio; Akihiko Tawara; Tomoko Tahira
Journal:  Mol Vis       Date:  2013-02-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.